ATE555807T1 - Catechine zur behandlung der fibrillogenese bei alzheimer-krankheit, parkinson-krankheit, systemischer aa-amyloidosis und anderer amyloid- störungen - Google Patents
Catechine zur behandlung der fibrillogenese bei alzheimer-krankheit, parkinson-krankheit, systemischer aa-amyloidosis und anderer amyloid- störungenInfo
- Publication number
- ATE555807T1 ATE555807T1 AT02721413T AT02721413T ATE555807T1 AT E555807 T1 ATE555807 T1 AT E555807T1 AT 02721413 T AT02721413 T AT 02721413T AT 02721413 T AT02721413 T AT 02721413T AT E555807 T1 ATE555807 T1 AT E555807T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- fibrillogenesis
- catechines
- amyloidosis
- parkinson
- Prior art date
Links
- 230000035557 fibrillogenesis Effects 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000023769 AA amyloidosis Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract 3
- 235000005487 catechin Nutrition 0.000 abstract 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 abstract 2
- 102100031639 Nascent polypeptide-associated complex subunit alpha Human genes 0.000 abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 2
- 229950001002 cianidanol Drugs 0.000 abstract 2
- 235000020688 green tea extract Nutrition 0.000 abstract 2
- 108010037351 nascent-polypeptide-associated complex Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 150000001765 catechin Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229940094952 green tea extract Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27686601P | 2001-03-15 | 2001-03-15 | |
| US33896901P | 2001-12-10 | 2001-12-10 | |
| PCT/US2002/007755 WO2003013442A2 (en) | 2001-03-15 | 2002-03-15 | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE555807T1 true ATE555807T1 (de) | 2012-05-15 |
Family
ID=26958170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02721413T ATE555807T1 (de) | 2001-03-15 | 2002-03-15 | Catechine zur behandlung der fibrillogenese bei alzheimer-krankheit, parkinson-krankheit, systemischer aa-amyloidosis und anderer amyloid- störungen |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1372682B1 (de) |
| JP (1) | JP2004537576A (de) |
| AT (1) | ATE555807T1 (de) |
| CA (1) | CA2440293C (de) |
| DK (1) | DK1372682T3 (de) |
| ES (1) | ES2387910T3 (de) |
| NZ (1) | NZ528321A (de) |
| PT (1) | PT1372682E (de) |
| WO (1) | WO2003013442A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514107B2 (en) | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
| US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| WO2004060791A1 (en) | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| EP1663199B1 (de) * | 2003-09-25 | 2013-04-03 | Tel Aviv University Future Technology Development L.P. | Zusammensetzungen und diese verwendende verfahren zur behandlung von amyloid-bedingten erkrankungen |
| WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| EP1713457A2 (de) * | 2004-02-11 | 2006-10-25 | Max-Delbrück-Centrum Für Molekulare Medizin | Neue arzneimittel und diagnostische zusammensetzungen f r be handlung und diagnose von neurodegenerativen erkrankungen und amyloid-krankheiten |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| US20100040558A1 (en) * | 2005-04-26 | 2010-02-18 | University Of South Florida | Green tea polyphenol alpha secretase enhancers and methods of use |
| JP2007022946A (ja) * | 2005-07-14 | 2007-02-01 | Mitsui Norin Co Ltd | マクロファージ遊走阻止因子の酵素活性阻害剤 |
| US10004828B2 (en) | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
| GB2463833B (en) * | 2007-06-26 | 2012-02-08 | Parkinson S Inst | Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders |
| JP5738755B2 (ja) * | 2008-05-09 | 2015-06-24 | アイカーン スクール オブ メディシン アット マウント シナイ | 神経変性疾患を予防および治療するための方法 |
| JP6068484B2 (ja) | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． | トランスサイレチン関連アミロイドーシスの新規療法 |
| US20180271927A1 (en) * | 2015-05-27 | 2018-09-27 | Nippon Paper Industries Co., Ltd. | Brain function-protecting agent |
| KR102441381B1 (ko) * | 2016-07-18 | 2022-09-07 | (주)아모레퍼시픽 | 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물 |
| JPWO2019054461A1 (ja) * | 2017-09-15 | 2020-08-27 | 株式会社明治 | 神経機能の維持または回復用組成物 |
| CN109799352B (zh) * | 2019-01-29 | 2022-03-08 | 北京健坤禾润科技有限公司 | 化学发光试剂及其在免疫检测中应用 |
| JP2025513275A (ja) * | 2022-04-20 | 2025-04-24 | サンテック メディカル，インコーポレイティド | 中枢神経系疾患の治療方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1275905B1 (it) * | 1995-03-14 | 1997-10-24 | Indena Spa | Frazioni polifenoliche di te', loro uso e formulazioni che le contengono |
| JPH10245342A (ja) * | 1997-03-03 | 1998-09-14 | Mitsui Norin Kk | β−アミロイド蛋白の神経細胞毒性低減剤 |
| WO1998051302A1 (en) * | 1997-05-15 | 1998-11-19 | University Of Washington | Composition and methods for treating alzheimer's disease and other amyloidoses |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| EP1246632A4 (de) * | 1999-12-30 | 2004-08-18 | Proteotech Inc | Katechine und grüntee-extrakt zur behandlung von amyloidosen generell bzw. bei alzheimer |
-
2002
- 2002-03-15 PT PT02721413T patent/PT1372682E/pt unknown
- 2002-03-15 WO PCT/US2002/007755 patent/WO2003013442A2/en not_active Ceased
- 2002-03-15 AT AT02721413T patent/ATE555807T1/de active
- 2002-03-15 ES ES02721413T patent/ES2387910T3/es not_active Expired - Lifetime
- 2002-03-15 EP EP02721413A patent/EP1372682B1/de not_active Expired - Lifetime
- 2002-03-15 CA CA2440293A patent/CA2440293C/en not_active Expired - Fee Related
- 2002-03-15 JP JP2003518456A patent/JP2004537576A/ja active Pending
- 2002-03-15 NZ NZ528321A patent/NZ528321A/en not_active IP Right Cessation
- 2002-03-15 DK DK02721413.9T patent/DK1372682T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ528321A (en) | 2006-09-29 |
| WO2003013442A2 (en) | 2003-02-20 |
| JP2004537576A (ja) | 2004-12-16 |
| EP1372682B1 (de) | 2012-05-02 |
| CA2440293C (en) | 2012-01-24 |
| DK1372682T3 (da) | 2012-08-20 |
| EP1372682A2 (de) | 2004-01-02 |
| WO2003013442A3 (en) | 2003-05-30 |
| EP1372682A4 (de) | 2005-10-19 |
| ES2387910T3 (es) | 2012-10-03 |
| CA2440293A1 (en) | 2003-02-20 |
| PT1372682E (pt) | 2012-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003013442A3 (en) | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| BG106095A (bg) | Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици | |
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| PT1326613E (pt) | Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos | |
| MY132784A (en) | "prevention and treatment of amyloidogenic disease" | |
| BR0315283A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de doenças neurológicas ou de doenças inflamatórias do trato respiratório superior | |
| ATE330585T2 (de) | Behandlung von atemerkrankungen | |
| DE60228857D1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| EA200501023A1 (ru) | Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида | |
| ATE401395T1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
| NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
| IL189546A0 (en) | Therapy for the treatment of disease | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| ATE529417T1 (de) | 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält | |
| DK1427396T3 (da) | Doseringsformer med forlænget frigivelse af aktivt indholdsstof | |
| WO2001053457A3 (en) | Vaccines against neurodegenerative disorders | |
| WO2002076381A3 (en) | Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases | |
| BRPI0409380A (pt) | composições farmacêuticas | |
| BR0308982A (pt) | Combinações de epinastina, beladona e pseudoefedrina como novas formulações farmacêuticas | |
| NO903384D0 (no) | Fremgangsmaate for fremstilling av 4-(n-substituert amino)-2-butynyl-1-urinstoffer og -tiourinstoffer og derivater derav. | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| WO2008057599A3 (en) | Methods for the treatment of abeta related disorders and compositions therefor | |
| MY131159A (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine |